Understanding human papillomavirus vaccine response and efficacy in people living with HIV
A systematic mixed studies review and meta-analysis
Bibliographic Data
| ID | 19594893 |
|---|---|
| Authors | Alvine Akumbom (0000-0002-6689-1104, Johns Hopkins University, corresponding author), Amanda J Bergman (0000-0003-1474-7765, University of Virginia, corresponding author), Howard D Strickler (0000-0002-7692-6147, Albert Einstein College of Medicine, corresponding author), Howard Strickler, Chakra Budhathoki (0000-0002-1886-7847, Johns Hopkins University, corresponding author), Manka Nkimbeng (0000-0001-7414-921X, University of Minnesota, corresponding author), Raeven Grant (0000-0002-9624-4389, University of California, Los Angeles, corresponding author), Nancy R Reynolds, Nancy Reynolds (0000-0002-5023-1953, Johns Hopkins University, corresponding author), Kawsar R Talaat (0000-0002-4899-6260, Johns Hopkins University, corresponding author) |
| Editors | Lei Gao (0000-0002-8961-1734) |
| Year | 2024 |
| Volume | 4 |
| Issue | 12 |
| Pages | e0003931 |
| Publication date | 2024-12-20 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | PLOS Global Public Health (JOURNAL) |
| Journal identifiers | ISSN: 2767-3375 • E-ISSN: 2767-3375 |
| Publisher | Public Library of Science (PLoS) (PUBLISHER) |
| DOI | 10.1371/journal.pgph.0003931 |
| PMID | 39705286 |
| OpenAlex | W4405634819 |
| Language | EN |
| Citations received | 1 |
| References cited | 53 |
Coinfection with human papillomavirus (HPV) and HIV compounds the risks of developing cervical, anal, and HPV-associated oral neoplasia. Safe prophylactic vaccines are available to prevent HPV infections in people with HIV(PWH). Yet, vaccine efficacy and duration of protection remain questionable. Historically, the efficacy of vaccines has been suboptimal in PWH compared to people without HIV (PWoH).A systematic review of HPV vaccine trials in PWH was conducted using PRISMA guidelines. Outcomes of interest were vaccine efficacy, immunogenicity, and predictors of HPV vaccine efficacy. A secondary outcome was to assess age and sex differences. Efficacy was reviewed as cervical/anal/oral lesions or neoplasia, and incident or persistent HPV infection following vaccination. A random effects meta-analysis was performed comparing geometric mean titer (GMT) in PWH to PWoH. Twenty-eight studies out of 988 were eligible for inclusion in our study, and qualitatively synthesized. Eight of these studies were meta-analyzed. GMT results of HPV16 and HPV18 genotypes were significantly lower in PWH; Hedges’s g -0.434 (95% CI: -0.823, -0.046) and Hedges’s g -0.57 (95% CI: -0.72, -0.43), respectively. The mean difference in GMT for HPV18 between PWH and PWoH was -536.23 (95% CI: -830.66, -241.81); approximately 22 times higher than HPV18 seropositivity cut-offs, assuming milli-Merck Units per milliliter. Risk factors for incident or persistent infections in PWH included: failure to seroconvert after vaccination, baseline CD4+ T-cell count
Cancer · Cervical cancer · Coinfection · HPV infection · HPV vaccines · Immune system · Immunogenicity · Meta-analysis · Vaccination · Vaccine efficacy · Cervical Cancer and HPV Research · Genital Health and Disease · Hepatitis B Virus Studies · Medicine · Immunology · Internal Medicine
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Human Papillomavirus Vaccination for Adults
Risk‐of‐bias VISualization (robvis)
The PRISMA 2020 statement
Robins-I
Quantifying heterogeneity in a meta‐analysis
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Human Papillomavirus Vaccination in South Africa
| Citations per year | 1 |
|---|---|
| Citation span | 2026 - 2026 (1) |
| Highly cited | No |